For nearly three decades, Alzheimer’s drug development lived under the shadow of a single protein: amyloid-beta. Even after monoclonal antibodies like lecanemab and donanemab proved that clearing amyloid plaques can modestly slow memory loss, neurologists knew a larger culprit remained largely untouched inside dying neurons—tau. Now, two-year clinical trial data unveiled at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston this week suggest that shutting down tau production at the RNA level may not only slow Alzheimer’s progression, but widen its protective lead over time.
On November 17, 2026, Biogen and Ionis Pharmaceuticals presented Week 96 open-label extension results from the global Phase 2 CELIA trial (NCT05399888) evaluating diranersen (formerly known as BIIB080 or IONIS-MAPTrx). Administered just twice a year at a 60 mg dose, the investigational antisense oligonucleotide (ASO) slowed cognitive decline by 54% on the ADAS-Cog13 scale and 38% on the CDR-SB scale at the two-year mark—accelerating past its 18-month results and signaling a potential paradigm shift toward precision RNA medicine in neurology.
Clinical Trial Snapshot: CELIA Week 96 Results (CTAD Nov 2026)
- Trial & Population: Global Phase 2 CELIA study enrolling 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia who had not previously received anti-amyloid therapy.
- Winning Regimen: 60 mg intrathecal injection every 24 weeks (just two doses per year), delivering the strongest balance of efficacy and tolerability.
- ADAS-Cog13 Slowing: Slowed cognitive decline by 54% at Week 96 (two years) relative to the placebo-equivalent control group—widening substantially from 42% at Week 76 (18 months).
- CDR-SB Slowing: Slowed clinical and functional decline by 38% at Week 96 (a 1.09-point treatment difference), nearly doubling the 26% slowing (0.54-point difference) seen at 18 months.
- Widening Trajectory & Safety: Treatment benefits deepened between 18 and 24 months across 5 of 6 cognitive, functional, and disease-progression measures, with no new safety signals observed through two years.
Why Targeting MAPT mRNA Solves What Anti-Tau Antibodies Missed
In Alzheimer’s pathology, amyloid-beta plaques accumulate outside neurons years before symptoms appear, often plateauing by the time a patient notices memory trouble. Tau neurofibrillary tangles behave differently: they spread progressively across cortical networks in tight lockstep with synaptic loss, brain atrophy, and cognitive decline. If amyloid is the match that sparks Alzheimer’s disease, tau is the fire that consumes neural circuitry.
Yet early anti-tau therapies repeatedly stumbled in clinical trials. Most of those first-generation candidates were monoclonal antibodies engineered to bind tau protein floating outside cells—an approach that left the vast intracellular pool of newly synthesized tau untouched. Diranersen attacks the problem one biological layer earlier.
Designed as a gapmer antisense oligonucleotide (ASO), diranersen is a short, chemically stabilized strand of synthetic genetic code delivered into the cerebrospinal fluid via intrathecal injection. Once inside brain cells, it binds selectively to messenger RNA transcribed from the MAPT gene—the molecular blueprint neurons use to manufacture tau protein. That binding triggers cellular enzymes to degrade the MAPT mRNA before tau protein can even be translated.
1. Upstream RNA Silencing
By degrading MAPT mRNA inside neurons, diranersen lowers both intracellular tau production and downstream extracellular tau release—something antibodies cannot do once proteins are already folded.
2. Deep Biomarker Clearance
Across CELIA sub-studies, suppressing tau synthesis produced broad reductions in tau PET brain imaging signals alongside steep drops in CSF p-tau181 and plasma p-tau217 biomarkers.
3. Twice-Yearly Durability
Because brain tau protein turns over slowly and ASOs remain active inside neural tissue for months, a single 60 mg dose every 24 weeks sustained deepening clinical separation through two full years.
The CELIA Plot Twist: Why 60 mg Twice Yearly Beat Higher Doses
The headline numbers from Boston carry an instructive scientific twist. Earlier in 2026, when Biogen first reported top-line Week 76 (18-month) results from CELIA, the study technically missed its formal primary dose-response endpoint. That statistical framework had assumed that escalating to higher or more frequent regimens—such as 115 mg every 24 weeks or 115 mg every 12 weeks—would yield proportionally larger clinical gains.
Instead, the biology of tau homeostasis favored moderation. Higher 115 mg regimens carried a greater incidence of serious adverse events without delivering superior cognitive protection, whereas the gentler 60 mg twice-yearly schedule hit an optimal therapeutic window. Crucially, when patients continued into the long-term extension through Week 96, the 60 mg curve didn’t flatten—it diverged even further from the placebo-equivalent baseline.
Why the 18-to-24 Month Divergence Matters:
If a therapy merely masked symptoms temporarily, its benefit would shrink or stabilize over time. Seeing CDR-SB slowing expand from 26% (0.54 points) at 18 months to 38% (1.09 points) at two years—while ADAS-Cog13 climbed from 42% to 54%—is precisely the signature neurologists look for in true disease-modifying neuroprotection.
Comparing Today’s Alzheimer’s Mechanisms Side by Side
To appreciate how diranersen fits into the rapidly evolving 2026 Alzheimer’s landscape—which also saw 36-month real-world Leqembi (LEADER) data at CTAD showing a 76% lower progression rate to moderate or severe dementia versus matched natural history cohorts—it helps to compare how each therapeutic class intervenes:
Caveats, Phase 3 Hurdles, and What Comes Next
Extraordinary caution is still warranted before declaring victory. Because Week 96 data come from an open-label extension compared against an original placebo-equivalent reference group rather than a fully blinded two-year randomized placebo arm, bias and dropout effects can subtly amplify late-stage effect sizes. Furthermore, intrathecal lumbar puncture delivery—even just twice a year—requires specialized outpatient clinical infrastructure, and the 60 mg dose must still prove itself in large, rigorously powered, randomized Phase 3 confirmatory trials before any FDA submission.
Even with those hurdles ahead, Biogen’s decision to advance diranersen toward Phase 3 marks a watershed moment for patients and caregivers. Looking ahead, neurologists envision a multi-pronged playbook that mirrors oncology and HIV care:
- Validating 60 mg Twice-Yearly in Phase 3: Confirming that Week 96’s 38% CDR-SB and 54% ADAS-Cog13 trajectories replicate in a global, randomized, double-blind pivotal cohort.
- Testing Amyloid-Plus-Tau Combination Therapy: Because CELIA enrolled anti-amyloid-naive patients, pairing upstream tau silencing with plaque-clearing antibodies could test whether hitting both pathologies simultaneously halts decline even further.
- Earlier Pre-Symptomatic Intervention: Coupling blood-based p-tau217 screening with twice-yearly RNA silencing could eventually allow clinicians to intercept tau accumulation before irreversible hippocampal damage occurs.
- Next-Generation Non-Invasive Delivery: Advances in blood-brain barrier shuttles and ligand-conjugated oligonucleotides may one day convert intrathecal ASOs into routine subcutaneous injections.
For decades, families facing an Alzheimer’s diagnosis were told that neurodegeneration was a one-way street with no durable brake. While Phase 3 confirmation remains essential, the November 2026 CTAD data demonstrate that silencing tau at its genetic source is no longer theoretical—and that a twice-yearly RNA shot could soon redefine what it means to protect the aging human brain.
Primary Sources & Official References
- ClinicalTrials.gov — Phase 2 CELIA Study of BIIB080 / Diranersen (NCT05399888)
- Biogen — Diranersen Two-Year CELIA Data (CTAD 2026)
- Ionis Pharmaceuticals — Tau-Targeting Antisense Pipeline (IONIS-MAPTrx)
- ALZFORUM — BIIB080 (Diranersen) Mechanism & Trial Tracker
- Clinical Trials on Alzheimer's Disease (CTAD 2026, Boston)






